BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026)

BioAge Labs (BIOA) reported Net Equity Issued and Repurchased of $124.3 million for Q1 2026, down 26.87% sequentially from $170.0 million in Q1 2024.

BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends

BioAge Labs (BIOA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $124.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $124.3 million; the trailing twelve-month figure through Mar 2026 stood at $124.3 million (changed N/A YoY), and the FY2024 full-year result was $170.0 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased slipped to $124.3 million in Q1 2026, from $170.0 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $170.0 million in Q1 2024 to a low of $124.3 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 500,000.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 23.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 BioAge Labs 930.32 Mn 930.32 Mn -10.37 Mn 124.32 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 124.32 Mn
Mar 31, 2026 124.32 Mn
Mar 31, 2024 170.00 Mn
Mar 31, 2024 170.00 Mn